LAROPIPRANT in English translation

• laropiprant

Examples of using Laropiprant in Danish and their translations into English

I Pelzont- tabletter er der laropiprant i et af lagene, mens det andet lag indeholder nikotinsyre.
In Pelzont tablets, laropiprant is in one of the layers, and the other layer contains nicotinic acid.

I Tredaptive- tabletter er der laropiprant i et af lagene, mens det andet lag indeholder nikotinsyre.
In Tredaptive tablets, laropiprant is in one of the layers, and the other layer contains nicotinic acid.

Startdosis er én tablet med modificeret udløsning(1. 000 mg nicotinsyre/ 20 mg laropiprant) én gang dagligt.
Posology The starting dose is one modified-release tablet(1000 mg nicotinic acid/ 20 mg laropiprant) once a day.

Laropiprant er i høj grad(>
Laropiprant is highly bound(>

Laropiprant har også affinitet til tromboxane A2- receptoren(TP)
Laropiprant also has affinity for the thromboxane A2 receptor(TP)

Efter en 40 mg dosis, når denne administreres som to tabletter med modificeret udløsning af nicotinsyre/ laropiprant efter en nats faste.
The mean absolute bioavailability of laropiprant is approximately 71% following a 40 mg dose when administered as two modified-release tablets of nicotinic acid/ laropiprant after an overnight fast.

over for nikotinsyre, laropiprant eller andre af indholdsstofferne.
to nicotinic acid, laropiprant or any of the other ingredients.

kan midazolams sedative virkning øges, og forsigtighed bør udvises, når laropiprant gives samtidigt med midazolam.
the sedative effect of midazolam may be increased and caution should be used when laropiprant is co-administered with midazolam.

Toksikologiske fund i disse undersøgelser af samtidig administration var i overensstemmelse med de fund, der blev gjort, når nicotinsyre og laropiprant blev administreret enkeltvis.
Toxicologic findings in these co-administration studies were consistent with those seen with nicotinic acid and laropiprant administered individually.

Samtidig administration af laropiprant 40 mg og midazolam øgede AUC0- ∞ og Cmax for 1'- hydroxymidazolam, en midazolammetabolit, med henholdsvis 98% og 59.
Co-administration of laropiprant 40 mg with midazolam increased the AUC0-∞ and Cmax of 1'-hydroxymidazolam, a midazolam metabolite, by 98% and 59%, respectively.

I en klinisk undersøgelse sås ingen relevant indvirkning af laropiprant på clopidogrels hæmning af ADP- induceret blodpladeaggregation,
In a clinical study, there was no meaningful effect of laropiprant on the inhibition of ADP-induced platelet aggregation by clopidogrel,

På basis af disse data forventes laropiprant ikke at medføre interaktion med substrater af CYP- isozymerne 3A4, 2C9, 2C8
Based on these data, laropiprant is not expected to cause interactions with substrates of CYP isozymes 3A4,

som i terapeutiske doser er et lipidmodificerende stof, og laropiprant, der er en potent, selektiv prostaglandin D2- antagonist(PGD2)
which at therapeutic doses is a lipid-modifying agent, and laropiprant, a potent, selective antagonist of the prostaglandin D2(PGD2)

Laropiprant I kontrollerede kliniske undersøgelser med raske forsøgspersoner var enkeltdoser af op til 900 mg laropiprant og multiple doser op til 450 mg én gang dagligt i 10 dage generelt veltålt.
Laropiprant During controlled clinical trials in healthy subjects, single doses of up to 900 mg laropiprant and multiple doses up to 450 mg once daily for 10 days were generally well tolerated.

medicin som ændrer indholdet af fedtstoffer i blodet og• laropiprant, som mindsker rødmen,
a lipid modifying medicine, and• laropiprant, which reduces symptoms of flushing,

Administration af laropiprant 40 mg til ikke- dialyserede patienter med svær nyreinsufficiens resulterede ikke i klinisk relevant forandring i laropiprants AUC
Administration of laropiprant 40 mg in non-dialysed patients with severe renal insufficiency resulted in no clinically meaningful change in the AUC

Laropiprant var ikke teratogent hos rotter
Laropiprant was not teratogenic in rats

Laropiprant er ikke et substrat af humant P- gp,
Laropiprant is not a substrate of human P-gp,

Laropiprant var ikke karcinogent i 2- års undersøgelser på mus
Laropiprant was not carcinogenic in 2 year studies in mice

hunrotter, der fik laropiprant før og under parring, ved systemiske eksponeringsniveauer,
female rats given laropiprant prior to mating